ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0696

MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers
Abstract Number: 0234

MRI of Sacroiliac Joints: Is Contrast Necessary for the Detection of Sacroiliitis?
Abstract Number: 1742

Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care
Abstract Number: 1490

Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Abstract Number: 2636

Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Abstract Number: 1762

Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk
Abstract Number: 1789

Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus
Abstract Number: 1706

Multi-omic Study in Patients with SITRAME Syndrome
Abstract Number: 2426

Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
Abstract Number: 0961

Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients
Abstract Number: 1632

Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
Abstract Number: 1665

Multicenter Randomized Controlled Trial of Physical Therapy (PT) or Sham PT in Persons with Knee Pain, Meniscal Tear, and Osteoarthritic Imaging Changes
Abstract Number: 2633

Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification
Abstract Number: 1307

Multidisciplinary Participation in Online Rheumatology Discussion Forums
Abstract Number: 2452

Multimodal Ultrasound in the Assessment of Sarcopenia-related Muscle Involvement in Patients with Systemic Sclerosis: A Multicentric Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].